Overall verdict
Neutral
3.9/10
1-year performance
+216.53%
Score breakdown
Up 216.5% over 1 year, 40% of the 52-week range.
Strongest: Financial strength 5.8/10. Weakest: Shareholder return 0.0/10.
Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer ;
and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. Cypherpunk Technologies Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Douglas Onsi
Founded
2011
Employees
6
Revenue / employee
0 USD
Next earnings
November 16, 2026 (Q3 2026)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC0.96%
- Bank of New York Mellon Corp0.08%
- Rest of the register98.97%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
4.19 USD
52-week low
0.41 USD
1-year performance
216.53%
Rising
Year-to-date performance
69.47%
Rising
Drawdown
-54.30%
Major drawdown
Position in the 52-week range
40% of range
ROIC -1.2%, ROE -1.2%.
Net margin
—
Sector -207.84%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
-1.21%
Negative
Sector -57.88%|S&P 17.06%
Return on invested capital (ROIC)
-1.21%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
0.0/10Revenue up 0.0% over 1 year, -100.0% a year over 5.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
0.00%
Declining
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
5.7/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
3.4x
Cheap
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
7.4x
Fair
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
0.02
Growth unpriced
Sector 0.13|S&P 0.91
P/E vs its own 5-year history
among the 17% highest valuations
At its historical high
Market cap
206M USD
Financial strength
5.8/10Cash covers 20063.2% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-5.45%
Net cash
Cash
7.6M USD
Cash / market cap
3.69%
Tight
Cash / total debt
20063.16%
Net cash
Interest coverage
-740.6x
Stretched
Net debt
-7.6M USD
Equity
139M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 2.13 USD
- MM202.79
- MM502.86
- MM2001.34
- RSI 1441.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+15.57%
200-day average slope, 3 months
+45.45%
50-day average slope, 1 month
+34.10%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
12.00 % per day
Volatility change
+22.23%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.04 (1) | -0.51 (1) | 42 (1) | — | -9 (1) |
| 2027 | 0.77 (1) | -0.09 (1) | 211 (1) | — | 186 (1) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 9, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | CYPH | 3.9 | 2.6 | 206M USD | 3.4x | — | 0.0 % | -1.2 % | — | -10.2 % | 216.5 % | ||
| 5 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 6 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.1 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
